Daria Tsyba, Research Scientist, Department of Early Drug Development, Geropharm.
A talk about how ML is applied in the early stages of development of protein-based drugs, what form of protein can be fed into the model, and why the data for each of these formats are "horrible." At the end, on a practical case, Random Forest and CatBoost are compared for predicting post-translational modification (deamidation) in candidate molecules.
Continue reading — it's free
Google or a one-time email code. No password.
